• Not Applicable

This phase three, double-blind, randomised, placebo-controlled, multicentre study was carried out in 30 countries. It compared riociguat (maximum dose 2.5 mg three times a day) with placebo in the treatment of symptomatic pulmonary hypertension.

The primary end point was change in baseline walking distance over 6 min assessed after 12 weeks of treatment. Patients in the riociguat group improved by …